Autoimmune Life Blog

BRI was formed with a clear plan: First, answer key fundamental questions about the immune system. Then, build on those answers to change lives. This is a very exciting time because we’re reaching that second stage of the plan.

Your gut is home to a huge community of bacteria called the microbiome. Some bacteria are good, some are bad — and some might hold the key to understanding an inflammatory bowel disease (IBD) like Crohn’s disease and ulcerative colitis.

A team led by Peter Linsley, PhD, and Karen Cerosaletti, PhD, recently uncovered a clue that could help solve the mystery of why and how T1D starts and maybe even open the door to new therapies that stop the disease.

One goal is to find markers that identify why some people with the virus don’t have symptoms while others get fatally ill. The sickest patients tend to have multiple health issues, which makes it hard to pinpoint the factors related to COVID-19.

Dr. Bolouri joined BRI’s growing Systems Immunology Division this year. Much of his work explores why some people have one immune response to an external or internal event, while other people have a different response. He and his systems immunology colleagues examine the big picture.

When some people are diagnosed with type 1 diabetes (T1D), the disease progresses so quickly that their pancreas stops making insulin within a year.  For others, the process is slower and this can make their T1D easier to manage.  But what if we could identify these fast progressors early, and ma

Immunotherapy is one of the biggest medical breakthroughs in decades: It can cure some cancers by telling the immune system to find and kill cancer cells.

BRI’s Matt Dufort, PhD, and Peter Linsley, PhD, led two new studies that could help doctors predict how quickly type 1 diabetes (T1D) will progress in some people, and match them with treatments that could slow it down. Dr.

When gene sequencing suddenly became affordable, researchers were confronted with an enormous opportunity – and an enormous problem.

Pioneering research on peanut allergies at Benaroya Research Institute at Virginia Mason (BRI) was recently fueled by a $5 million grant from the National Institutes of Health to accelerate discovery of treatments.